HAMP and anemia: Minihepcidins, which are hepcidin agonists, improve anemia and iron overload in young β-thalassemia model Hbbth3/+ mice, and enhance erythropoiesis without altering the beneficial effect of the iron chelating agent DFO on iron overload in older β-thalassemia mice.413,414 These findings suggest that minihepcidins have the potential to be a future treatment for β-thalassemia.